Accelerated radiotherapy in locally advanced head and neck cancer – early results

«Radiation and Risk», 2018, vol. 27, no. 2, pp.107-116

DOI: 10.21870/0131-3878-2018-27-2-107-116


Gordon K.B. – Researcher, C. Sc., Med. A. Tsyb MRRC, Obninsk, Russia. Contacts: 4 Korolyov str., Obninsk, Kaluga region, Russia, 249036. Tel.: (484) 399-33-91; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. .
Gulidov I.A. – Head of Dep., D. Sc., Med., Prof. A. Tsyb MRRC, Obninsk, Russia.
Semenov A.V. – Jun. Res. A. Tsyb MRRC, Obninsk, Russia.
Radzhapova M.U. – Lead. Res., C. Sc., Med. A. Tsyb MRRC, Obninsk, Russia.
Sevrukov F.E. – Head of Dep., C. Sc., Med. A. Tsyb MRRC, Obninsk, Russia.


The aim of the research was to evaluate the immediate efficacy and early toxicity of radiation therapy for locally advanced head and neck squamous cell carcinoma of the III-IVB stages. We used accelerated radiotherapy as independent form or in combination with chemotherapy. The material is presented by the results of treatment of 69 patients diagnosed with squamous cell carcinoma of the head and neck of the III-IVB stages. Mucositis grade 3-4 occurred in 7 (43.8%) patients in radiotherapy alone group, 9 (32.2%) patients in the induction chemotherapy group, 8 (32.0%) patients in the group of simultaneous chemoradiation treatment. Continuous treatment was conducted in 46 (66.6%) patients. Treatment with forced interruption was conducted in 23 (33.4%) patients. All patients (100%) who received a course of radiotherapy in an independent version transferred it without interruption. In the group with induction chemotherapy, there were 42.8%, and simultaneous – 20.8%. An objective tumor response to radiotherapy was registered in 63 (91.3%) patients. Significantly more often objective response was obtained in groups with induction and simultaneous chemotherapy. Differences were found in favor of adding to the treatment regimen locally advanced forms of head and neck cancer of chemotherapy in any of the variations (in comparison with radiotherapy alone) at the level of the statistical trend (p<0.05). The median follow-up was 5.5 months, the mean follow-up was 7.3 months. The 3-month overall survival of patients was 93.8±2.9%, 6-month – 84.0±4.9%, 9-month – 75,4±6.4%, 12-month – 71.8±7.0%. The level of local control for 3 months was 92.1±3.3%, 6 months – 83.3±5.1%, 9 months – 68.4±7.9%, 12 months – 66.1±8.3%. The obtained data testify to the good tolerability of radiation therapy in the regime of accelerated fractionation in an independent variant and in combination with induction chemotherapy. The combination of accelerated radiotherapy with simultaneous chemotherapy requires careful selection of patients.

Key words
Head and neck cancer, radiation therapy, induction chemotherapy, simultaneous chemotherapy, radiation reactions, overall survival, disease-free survival, treatment results, accelerated fractionation, altered fractionation.


1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin., 2011, vol. 61, no. 2, pp. 69-90.

2. Sostoyanie onkologicheskoy pomoshchi naseleniyu Rossii v 2015 godu [The state of cancer care for the Russian population in 2014]. Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow, P. Hertsen Moscow Oncology Research Center, branch of NMRRC Publ., 2015. pp. 31-32.

3. Locally Advanced Squamous Carcinoma of the Head and Neck. Review of Cancer Medicines on the WHO List of Essential Medicines, 2014. pp. 1-8. Available at: expert/20/applications/HeadNeck.pdf (Accessed 19 May 2018).

4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Head and neck cancer. Version 2.2017. Available at: (Accessed 19 May 2018).

5. Practical recommendations for the treatment of malignant tumors of the head and neck RUSSCO. Version 2016. DOI: 10.18027/2224-5057-2016-4s2-55-63. (In Russian).

6. Gordon K.B., Rozhnov V.A., Gulidov I.A., Andreev V.G., Kurpeshev O.K. Rol' radiomodifikatsii v luchevom lechenii nerezektabel'nogo raka gortani [The role of radiomodification for radiotherapy of unresectable laryngeal cancer]. Onkologiya. Zhurnal im. P.A. Gertsena – P.A. Herzen Journal of Oncology, 2015, vol. 4, no. 6, pp. 13-19.

7. Denaro N., Russi E.G., Merlano M.C. Strategies for non-resectable head and neck cancer. Curr. Treat. Options Oncol., 2013, vol. 14, no. 4, pp. 492-504.

8. Overgaard J., Hansen H.S., Specht L. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet, 2003, vol. 362, no. 9388, pp. 933-940.

9. Saunders M.I., Rojas A.M., Parmar M.K., Dische S.; CHART Trial Collaborators. Mature results of a randomized trial of accelerated hyperfractionated versus conventional radiotherapy in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys., 2010, vol. 77, no. 1, pp. 3-8.

10. Budach W., Hehr T., Budach V., Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer, 2006, vol. 6, p. 28.

11. Pankratov V.A., Andreev V.G., Mardynskiy Y.S., Rozhnov V.A., Kurpeshev O.K., Akki E.D. Sovremennye vozmozhnosti konservativnogo i kombinirovannogo lecheniya mestnorasprostranennogo raka gortani [Modern possibilities of conservative and combined treatment of locally advanced laryngeal cancer]. Sibirskiy onkologicheskiy zhurnal – Siberian Journal of Oncology, 2013, no. 2, pp. 36-40.

12. Bourhis J., Overgaard J., Audry H., Ang K.K., Saunders M., Bernier J., Horiot J.C., Le Maître A., Pajak T.F., Poulsen M.G., O'Sullivan B., Dobrowsky W., Hliniak A., Skladowski K., Hay J.H., Pinto L.H., Fallai C., Fu K.K., Sylvester R., Pignon J.P.; MARCH Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet, 2006, vol. 368, no. 9538, pp. 843-854.

13. Gordon K.B., Gulidov I.A., Rozhnov V.A., Podlesnykh N.I., Pankratov V.A. Luchevaya terapiya nerezektabel'nogo raka gortani [Radiotherapy of unresectable laryngeal cancer]. Sibirskiy onkologicheskiy zhurnal – Siberian Journal of Oncology, 2016, vol. 15, no. 3, pp. 72-77.

14. Mardynskiy Y.S., Gulidov I.A., Ivanova I.N. Rezul'taty primeneniya rezhima uskorennogo giperfraktsionirovaniya v lechenii nemelkokletochnogo raka legkogo [Results of application of the accelerated hyperfractionation regime in the treatment of non-small cell lung cancer]. Sibirskiy onkologicheskiy zhurnal – Siberian Journal of Oncology, 2010, no. 2, pp. 11-14.

15. Gulidov I.A., Mardynskij Y.S. Novye vozmozhnosti dlja protonnoj terapii v Rossii [New opportunities for proton therapy in Russia]. Voprosy onkologii – Problems in Oncology, 2016, vol. 62, no. 5, pp. 570-572.

16. Atlas po klassifikatsii stadiy zlokachestvennykh opukholey (TNM) 2-e izdanie [TNM Classification of Malignant Tumours, second edition]. Russ. eds.: A.D. Kaprin, A.K. Trakhtenberg. Moscow, Prakticheskaya Meditsina Publ., 2014. 650 p.

17. Cannon D.M., Geye H.M., Hartig G.K., Traynor A.M., Hoang T., McCulloch T.M., Wiederholt P.A., Chappell R.J., Harari P.M. Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy. Head Neck, 2014, vol. 36, no. 8, pp. 1120-1125.

18. Suwinski R., Sowa A., Rutkowski T., Wydmanski J., Tarnawski R., Maciejewski B. Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. Int. J. Radiat. Oncol. Biol. Phys., 2003, vol. 56, no. 2, pp. 399-412.

19. Joiner M.C., van der Kogel A. Basic Clinical Radiobiology. 4th Edition. Russ. ed. Moscow, Binom Publ., 2013. 250 p. (In Russian).

20. Yarmonenko S.P., Vaynson A.A., Kalendo G.S., Rampan Y.I. Biologicheskie osnovy luchevoy terapii opukholey [Biological basis of tumors radiation therapy]. Moscow, Meditsina Publ., 1976. 272 p.

Full-text article (in Russian)